Need help finding what you are looking for?
Contact Us
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1480955
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1480955
Artificial Intelligence (AI) in Drug Discovery
PUBLISHED:
PAGES: 219 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Global Artificial Intelligence (AI) in Drug Discovery Market to Reach $12 Billion by 2030
The global market for Artificial Intelligence (AI) in Drug Discovery estimated at US$2.3 Billion in the year 2023, is expected to reach US$12 Billion by 2030, growing at a CAGR of 26.3% over the analysis period 2023-2030. AI in Oncology Drug Discovery, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the AI in Neurodegenerative Diseases Drug Discovery segment is estimated at 24% CAGR for the next 7-year period.
The U.S. Market is Estimated at $751.4 Million, While China is Forecast to Grow at 25.7% CAGR
The Artificial Intelligence (AI) in Drug Discovery market in the U.S. is estimated at US$751.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 25.7% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 23% and 22.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 18.5% CAGR.
Introducing Our Exciting New Report Features for 2024
Full access to influencer engagement stats
Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
Complimentary report updates for one year
Competitor coverage with global market shares of major players
Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
Select Competitors (Total 293 Featured) -
- Atomwise, Inc.
- Benevolentai
- Berg LLC
- Bioage
- Cloud Pharmaceuticals, Inc.
- Cyclica
- Deep Genomics
- Envisagenics
- Exscientia
- Google (A Subsidiary of Alphabet Inc.)
- IBM Corporation
- Insilico Medicine
- Microsoft Corporation
- Numedii, Inc.
- Numerate
- NVIDIA Corporation
- Owkin, Inc.
- Twoxar, Incorporated
- Verge Genomics
- Xtalpi, Inc.
Product Code: MCP21177
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Artificial Intelligence (AI) in Drug Discovery - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 2: World 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
- TABLE 3: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 4: World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 6: World 7-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Metabolic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 8: World 7-Year Perspective for Metabolic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
- TABLE 9: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 10: World 7-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 12: World 7-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 14: World 7-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
- TABLE 15: World Recent Past, Current & Future Analysis for Drug Optimization & Repurposing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 16: World 7-Year Perspective for Drug Optimization & Repurposing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Preclinical Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 18: World 7-Year Perspective for Preclinical Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
- TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 20: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
- TABLE 21: World Artificial Intelligence (AI) in Drug Discovery Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
- UNITED STATES
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 22: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 23: USA 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 24: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 25: USA 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- CANADA
- TABLE 26: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 27: Canada 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 28: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 29: Canada 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- JAPAN
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 30: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 31: Japan 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 32: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 33: Japan 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- CHINA
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 34: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 35: China 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 36: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 37: China 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- EUROPE
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 38: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 39: Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
- TABLE 40: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 41: Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 42: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 43: Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- FRANCE
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 44: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 45: France 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 46: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 47: France 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- GERMANY
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 48: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 49: Germany 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 50: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 51: Germany 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- ITALY
- TABLE 52: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 53: Italy 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 54: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 55: Italy 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- UNITED KINGDOM
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 56: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 57: UK 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 58: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 59: UK 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- REST OF EUROPE
- TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 61: Rest of Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 63: Rest of Europe 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- ASIA-PACIFIC
- Artificial Intelligence (AI) in Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 65: Asia-Pacific 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 67: Asia-Pacific 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
- REST OF WORLD
- TABLE 68: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 69: Rest of World 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease and Other Therapeutic Areas for the Years 2024 & 2030
- TABLE 70: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Drug Discovery by Application - Drug Optimization & Repurposing, Preclinical Testing and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 71: Rest of World 7-Year Perspective for Artificial Intelligence (AI) in Drug Discovery by Application - Percentage Breakdown of Value Sales for Drug Optimization & Repurposing, Preclinical Testing and Other Applications for the Years 2024 & 2030
IV. COMPETITION
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.